Company Encyclopedia
View More
name
Xilio Therapeutics
XLO.US
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
1.935 T
XLO.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking304/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-908.28%E
    • Profit Margin-183.90%E
    • Gross Margin24.89%C
  • Growth ScoreA
    • Revenue YoY588.40%A
    • Net Profit YoY6.87%C
    • Total Assets YoY79.08%A
    • Net Assets YoY-138.60%E
  • Cash ScoreB
    • Cash Flow Margin-54.38%D
    • OCF YoY588.40%A
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreE
    • Gearing Ratio106.05%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Xilio Therapeutics Inc. held special shareholder meeting

    Xilio Therapeutics Inc. held a special shareholder meeting on November 21, 2025, where stockholders approved a one-time repricing of certain employee stock options and the 2025 Stock Incentive Plan. They also approved a proposal to allow adjournment of the meeting if necessary. This information was published via EDGAR by Xilio Therapeutics Inc.

    Reuters·
    US
    XLO
    -1.08%
    Reuters·
    US
    XLO
    -1.08%

    Xilio Therapeutics Reports Revenue Growth Amidst Challenges

    Xilio Therapeutics Inc. reported Q3 earnings with a significant increase in collaboration and license revenue to $19.1 million from $2.3 million last year. Despite revenue growth, the company faced a net loss of $16.3 million due to increased R&D expenses, which rose to $21 million. The fair value change of common stock warrant liabilities also negatively impacted results. Xilio remains focused on advancing its immuno-oncology therapies and securing additional capital amidst financial sustainability challenges.

    Tip Ranks·
    US
    XLO
    -1.08%
    Tip Ranks·
    US
    XLO
    -1.08%

    Broadwind Announces Third Quarter 2025 Results

    Broadwind announced its third quarter 2025 results, reporting a 25% increase in revenue to $44.2 million and a net income of $7.5 million. The company raised its full-year revenue guidance, driven by strong demand in power generation and renewables markets. Broadwind completed the sale of its industrial fabrication operations, gaining $8.2 million, and received $11 million in new tower orders. The company has $26.8 million in cash and liquidity, with net leverage below 1.0x, supporting its growth strategy.

    fidelity·
    US
    BWEN
    +6.06%
    fidelity·
    US
    BWEN
    +6.06%

    Xilio Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 19.07 M

    LB filings·
    US
    XLO
    -1.08%
    LB filings·
    US
    XLO
    -1.08%

    Xilio Therapeutics' Q3 collaboration revenue rises

    Xilio Therapeutics' Q3 collaboration revenue increased to $19.1 million from $2.3 million year-over-year. However, the net loss for Q3 widened to $16.3 million from $14.0 million. The company anticipates a cash runway into Q1 2027 and plans to submit an IND for XTX501 in mid-2026. R&D expenses rose to $14.3 million from $10.8 million. Analysts rate the stock as a 'strong buy' with a median 12-month price target of $2.00, 61.3% above its current price of $0.77.

    Reuters·
    US
    XLO
    -1.08%
    Reuters·
    US
    XLO
    -1.08%
    © 2025 Longbridge｜Disclaimer